As reported on BioSpace, BridgeBio Pharma has reported new findings suggesting that its transthyretin (TTR) stabilizer, Attruby (acoramidis), may help preserve kidney function in patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM), potentially providing a competitive advantage in an increasingly crowded treatment landscape.
The data come from a post hoc analysis combining results from a Phase 2 study and the pivotal Phase 3 ATTRibute-CM trial, which supported Attruby’s FDA approval in November 2024. Researchers evaluated kidney-related outcomes over a follow-up period of up to 30 months.
According to the analysis, patients receiving Attruby experienced an early decline in estimated glomerular filtration rate (eGFR), a standard measure of kidney function. However, this initial reduction appeared to be reversible. Over longer-term follow-up, investigators observed a favorable change in the rate of eGFR decline compared with placebo, suggesting preservation of kidney function.
The company also reported sustained improvements in urinary albumin-to-creatinine ratio, a biomarker commonly used to assess kidney damage. Together, the findings indicate that Attruby may offer benefits extending beyond its established effects on cardiac disease progression.
Investment firm Jefferies described the results as evidence of potential “cardiorenal” protection, noting that the magnitude of kidney-function preservation appears comparable to that seen with therapies designed specifically for kidney disease. The analysts suggested that slowing kidney deterioration could ultimately contribute to better clinical outcomes, including reduced hospitalization rates and lower mortality risk.
The reported renal effects may also help differentiate Attruby from other therapies approved or under development for ATTR-CM. Jefferies highlighted Pfizer’s tafamidis products, Vyndaqel and Vyndamax, as the current market leaders in the indication, while noting that kidney-related benefits have not been a key distinguishing feature among existing treatments.
Competition in ATTR-CM is expected to intensify. AstraZeneca and Ionis Pharmaceuticals are evaluating Wainua (eplontersen), currently approved for hereditary transthyretin-mediated amyloidosis with polyneuropathy, in a Phase 3 study for ATTR-CM. Results from that trial are anticipated later this year and could influence the future treatment landscape.
The Attruby findings add to a series of recent positive developments for BridgeBio. The company recently announced encouraging late-stage data for infigratinib in achondroplasia, demonstrating improvements not only in growth but also in body proportionality. Analysts have identified those outcomes as another potential differentiator, arguing that improved proportionality may have meaningful implications for mobility and daily functioning.
While the kidney-related observations for Attruby emerged from a retrospective analysis and will require further validation, they offer additional evidence that the therapy could deliver broader clinical benefits for patients with ATTR-CM, strengthening BridgeBio’s position in a rapidly evolving amyloidosis market.
